NADP Annual Meeting, 22 May 2019, Paushuize, Utrecht ‘Accelerating antibiotic development in Europe’
16 April 2019

The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled ‘Accelerating antibiotic development in Europe‘.
The symposium will take place on 22 May 2019, 12:00 – 17:00 hrs. The venue of the meeting is Paushuize, Kromme Nieuwegracht 49, 3512 HE Utrecht. Participation is free, but registration is required through https://goo.gl/forms/gfLeU092Cx1BuHho2.
Prior to the symposium (between 9:30 – 12:00 hrs), we offer you the possibility to meet with Seamus O’Brian from the Global Antibiotic Research and Development Partnership (GARDP). GARDP (www.gardp.org) is a not-for-profit R&D organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavoring to ensure their sustainable access. If you are interested in scheduling an appointment (20-30 min.), please let us know by mailing your request to supportoffice@nadp.nl.
Programme
12:00-13:00
|
Registration | light lunch provided |
13:00-13:10 | Welcome |
13:10-13:20 | NADP update Cees de Joncheere, chairman NADP Executive Board |
13:20-14:05 | Bacteriophages and infection, an alternative treatment or an evidence-based alternative? Colin Hill, University College Cork, Ireland |
14:05-14:25 | GARDP: Public health driven antibiotic development Seamus O’Brian, GARDP |
14:25-14:45 | NADP Vouchers: Next generation antibiotics to fight global antimicrobial resistance Leonie de Best, Madam Therapeutics |
14:45-15:15 | Break |
15:15-16:00 | Unconventional strategies to find drugs aganst an unconvential pathogen: how to tackle TB Wilbert Bitter, VU University & Amsterdam UMC |
16:00-16:20 | Towards a European clinical trial network for new antimicrobial agents Marc Bonten, UMC Utrecht |
16:20-16:40 | NACTAR: The lugdunomycins, a new class of polyketide antibiotics with unique chemical scaffold Gilles van Wezel, Leiden University |
16:40-17:00 | NACTAR: Boosting host immunity against bacterial infections via therapeutic antibodies Frank Beurskens, Genmab |
17:00-18:00 | Drinks |